Pharsight

Nextstellis patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7732430 MAYNE PHARMA Drug delivery system comprising a tetrahydroxilated estrogen for use in hormonal contraception
Mar, 2025

(8 months from now)

US11793760 MAYNE PHARMA Orodispersible dosage unit containing an estetrol component
Jun, 2036

(12 years from now)

Nextstellis is owned by Mayne Pharma.

Nextstellis contains Drospirenone; Estetrol.

Nextstellis has a total of 2 drug patents out of which 0 drug patents have expired.

Nextstellis was authorised for market use on 15 April, 2021.

Nextstellis is available in tablet;oral dosage forms.

Nextstellis can be used as use by females of reproductive potential to prevent pregnancy.

Drug patent challenges can be filed against Nextstellis from 15 April, 2025.

The generics of Nextstellis are possible to be released after 17 June, 2036.

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Apr 15, 2026

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using DROSPIRENONE; ESTETROL ingredient

NCE-1 date: 15 April, 2025

Market Authorisation Date: 15 April, 2021

Treatment: Use by females of reproductive potential to prevent pregnancy

Dosage: TABLET;ORAL

More Information on Dosage

NEXTSTELLIS family patents

Family Patents